“World Series” Trial: Verdict Against Mircera Gives Amgen ESA Market Hold

While Roche is considering whether to appeal a jury verdict that its anti-anemia drug Mircera infringes Amgen's erythropoietin patents covering Epogen and Aranesp, Amgen is likely to retain its dominance over the $6 billion-plus erythropoiesis-stimulating agents market for some time